The Life Sciences team advised Syneron Bio on a strategic collaboration with AstraZeneca to develop potential first-in-class macrocyclic peptides for the treatment of chronic diseases. Under this collaboration, AstraZeneca will gain access to Syneron Bio's innovative Synova™ platform, an intelligent and high-throughput macrocyclic peptide drug research and development platform, designed to support the advancements of research programmes exploring possible future treatments of chronic diseases, including rare, autoimmune, and metabolic disease. AstraZeneca will provide upfront payments and potential near-term milestone payments totaling $75 million and up to $3.4 billion in additional development and commercial milestones. As a result of this collaboration, Syneron Bio plans to expand its Beijing R&D center.
Syneron Bio is a biotech company dedicated to the development of next-generation macrocyclic peptide therapeutics, employing its proprietary Synova™ platform. The company has built a robust pipeline targeting oncology and chronic diseases. With a team experienced in drug development and data science, Syneron Bio has completed multiple rounds of equity financing in less than three years, backed by multiple leading venture capital funds.
The Goodwin team was led by Wenseng “Wendy” Pan and included Kevin Guan, Longfei Fang, Yichen Xu, Cecilia Chen, Justin C. Pierce, Gozde Guckaya, William J. Harrington, Daniel S. Karelitz, and Clark Zhang.
For more information on the deal, please read the press release.